Genetic Predictors of Benefit to Pembrolizumab

Clinical trial NCT02710396 · TERMINATED

Trial details

NCT number: NCT02710396
Sponsor: Columbia University
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2016-05-31
Primary completion: 2021-03-10
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.